Xue, Yonger https://orcid.org/0000-0002-6022-2487
Hou, Xucheng https://orcid.org/0000-0001-7833-8704
Wang, Siyu
Zhang, Yuebao
Zhong, Yichen https://orcid.org/0000-0003-3652-1257
Kang, Diana D.
Wang, Chang https://orcid.org/0009-0005-1630-9453
Li, Haoyuan
Yu, Changyue https://orcid.org/0000-0003-1308-4269
Liu, Zhengwei https://orcid.org/0009-0003-5105-6709
Tian, Meng
Cao, Dinglingge https://orcid.org/0009-0007-3776-7474
Zheng, Ya Ying
Deng, Binbin
Hamon, Pauline
Merad, Miriam https://orcid.org/0000-0002-4481-7827
Dong, Yizhou https://orcid.org/0000-0001-5786-0659
Funding for this research was provided by:
Icahn School of Medicine at Mount Sinai
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM144117)
Article History
Received: 12 May 2025
Accepted: 27 October 2025
First Online: 26 November 2025
Competing interests
: Y.D. is a cofounder and holds equity in Immunanoengineering Therapeutics. The other authors declare no competing interests.